Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 A775_G776insYVMA||lung non-small cell carcinoma||sensitive||Ado-trastuzumab emtansine||Case Reports/Case Series||Actionable||In a Phase II trial, Kadcyla (ado-trastuzumab emtansine) treatment demonstrated limited efficacy in patients with relapsed non-small cell lung cancer harboring ERBB2 (Her2) mutations, resulting in a partial response in 20% (1/5) and stable disease in 60% (3/5) of patients harboring ERBB2 (HER2) A775_G776insYVMA (PMID: 29313813).||29313813|
|ERBB2 A775_G776insYVMA||lung non-small cell carcinoma||sensitive||Ado-trastuzumab emtansine||Preclinical - Pdx||Actionable||In a preclinical study, treatment with Kadcyla (ado-trastuzumab emtansine) resulted in tumor growth inhibition and tumor regression of patient derived xenograft (PDX) models harboring ERBB2 A775_G776insYVMA, but to a lesser degree than treatment with Pyrotinib (PMID: 30596880; NCT02535507).||30596880|
|PubMed Id||Reference Title||Details|
|(30596880)||HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.||Full reference...|
|(29313813)||A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.||Full reference...|